Tribute Pharmaceuticals Canada (SLRXF) 10-Q 10 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014
Document And Entity Information	'
Entity Registrant Name	'Tribute Pharmaceuticals Canada Inc.
Entity Central Index Key	'0001159019
Document Type	'10-Q
Document Period End Date	30-Sep-14
Amendment Flag	'false
Current Fiscal Year End Date	'--12-31
Is Entity a Well-known Seasoned Issuer?	'No
Is Entity a Voluntary Filer?	'No
Is Entity's Reporting Status Current?	'Yes
Entity Filer Category	'Smaller Reporting Company
Entity Common Stock, Shares Outstanding	94,476,238
Document Fiscal Period Focus	'Q3
Document Fiscal Year Focus	'2014

CONDENSED_INTERIM_BALANCE_SHEE

CONDENSED INTERIM BALANCE SHEETS (Unaudited) (CAD)	Sep. 30, 2014	Dec. 31, 2013
ASSETS	'	'
Cash and cash equivalents	28,725,849	2,813,472
Accounts receivable, net of allowance of $nil (2013 - $nil) (Note 16d)	1,922,835	591,766
Inventories (Note 2)	857,206	1,044,831
Taxes recoverable	47,481	651,791
Loan receivable	15,814	15,814
Prepaid expenses and other receivables (Note 3)	232,461	165,886
Current portion of debt issuance costs, net (Note 6)	121,992	91,100
Other current asset (Note 17)	13,158	0
Total current assets	31,936,796	5,374,660
Property, plant and equipment, net (Note 4)	1,026,008	1,089,919
Intangible assets, net (Note 5)	9,378,881	9,717,173
Goodwill	3,599,077	3,599,077
Debt issuance costs, net (Note 6)	286,925	253,712
Total assets	46,227,687	20,034,541
Current	'	'
Accounts payable and accrued liabilities	3,340,542	3,284,756
Current portion of long term debt (Note 6)	737,263	204,700
Warrant liability (Note 7 c)	3,250,811	2,966,714
Other current liability (Note 17)	0	38,156
Total current liabilities	7,328,616	6,494,326
Long term debt (Note 6)	7,645,299	5,640,102
Total liabilities	14,973,915	12,134,428
Contingencies and commitments (Notes 6 and 10)	'	'
SHAREHOLDERS' EQUITY	'	'
AUTHORIZED Unlimited Non-voting, convertible redeemable and retractable preferred shares with no par value Unlimited Common shares with no par value ISSUED (Note 7 a) Common shares 94,476,238 (2013 - 51,081,238)	41,189,440	19,947,290
Additional paid-in capital options (Note 7b)	2,646,881	2,286,890
Warrants (Note 7 c)	6,347,349	0
Accumulated other comprehensive loss (Note 17)	13,158	-38,156
Deficit	-18,943,056	-14,295,911
Total shareholders' equity	31,253,772	7,900,113
Total liabilities and shareholders' equity	46,227,687	20,034,541

CONDENSED_INTERIM_BALANCE_SHEE1

CONDENSED INTERIM BALANCE SHEETS (Parenthetical)	Sep. 30, 2014		Dec. 31, 2013
Shareholders Equity	'		'
Common Shares Authorized	'	[1]	'	[1]
Common Shares Issued	94,476,238		51,081,238
[1]	Unlimited

CONDENSED_INTERIM_STATEMENTS_O

CONDENSED INTERIM STATEMENTS OF OPERATIONS, COMPREHENSIVE (LOSS) AND DEFICIT (Unaudited) (CAD)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues	'	'	'	'
Licensed domestic product net sales	2,381,710	2,242,333	7,121,403	6,378,621
Other domestic product sales	991,053	790,362	2,945,936	2,618,710
International product sales	496,153	347,551	1,318,002	1,037,103
Royalty and licensing revenues	0	99,884	18,414	197,924
Total revenues (Notes 11 and 14)	3,868,916	3,480,130	11,403,755	10,232,358
Cost of Sales	'	'	'	'
Licensor sales and distribution fees	1,525,103	1,501,243	4,457,240	4,262,968
Cost of products sold	438,104	389,105	1,252,370	1,212,448
Expired products	25,228	20,253	38,584	20,253
Total Cost of Sales	1,988,435	1,910,601	5,748,194	5,495,669
Gross profit	1,880,481	1,569,529	5,655,561	4,736,689
Expenses	'	'	'	'
Selling, general and administrative (Notes 7b, 12 and 15)	2,529,534	2,224,457	8,161,873	7,681,179
Amortization of assets	296,723	313,635	883,649	977,693
Total operating expenses	2,826,257	2,538,092	9,045,522	8,658,872
Loss from operations	-945,776	-968,563	-3,389,961	-3,922,183
Non-operating income (expenses)	'	'	'	'
(Loss) on derivative instrument (Note 17)	-184,113	0	-180,913	0
Change in warrant liability (Note 7c)	4,454,565	-660,325	-163,184	-1,510,800
Accretion expense (Note 6)	-36,738	-20,895	-102,264	-68,123
Loss on disposal of intangible asset	'	-161,200	0	-161,200
Loss on extinguishment of loan	'	-620,835	0	-620,835
Interest income	57,550	268	58,088	2,235
Interest expense	-303,613	-152,026	-868,911	-320,029
Income (loss) before tax	3,041,875	-2,583,576	-4,647,145	-6,600,935
Deferred income tax recovery (Note 13)	0	0	0	314,900
Net income (loss) for the period	3,041,875	-2,583,576	-4,647,145	-6,286,035
Unrealized gain on derivative instrument, net of tax (Note 17)	13,158	0	13,158	0
Net income (loss) and comprehensive income (loss) for the period	3,055,033	-2,583,576	-4,633,987	-6,286,035
Deficit, beginning of period	-21,984,931	-11,426,015	-14,295,911	-7,723,556
Deficit, end of period	-18,943,056	-14,009,591	-18,943,056	-14,009,591
Earnings (loss) per share (Note 8) – Basic and diluted	0.03	-0.05	-0.07	-0.13
Weighted Average Number of Common Shares – Basic	87,948,738	50,985,538	64,283,839	48,525,136
Weighted Average Number of Common Shares - Diluted	88,392,327	50,985,538	64,283,839	48,525,136

CONDENSED_INTERIM_STATEMENTS_O1

CONDENSED INTERIM STATEMENTS OF CASH FLOWS (Unaudited) (CAD)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from (used in) operating activities	'	'
Net (loss)	-4,647,145	-6,286,035
Items not affecting cash:	'	'
Deferred income tax (recovery)	0	-314,900
Amortization	909,311	995,758
Changes in warrant liability (Note 7c)	163,183	1,510,800
Loss on extinguishment of loan	0	620,835
Loss on disposal of intangible asset	0	161,200
Stock-based compensation (Note 7b)	359,992	428,482
Accretion expense	102,264	68,123
Paid-in common shares for services (Note 7a)	211,812	0
Change in non-cash operating assets and liabilities (Note 9)	-736,585	-2,629,186
Cash flows (used in) operating activities	-3,637,168	-5,444,922
Cash flows from (used in) investing activities	'	'
Additions to property, plant and equipment	-6,525	-25,562
Payment of contingent liability	0	-460,000
Increase in intangible assets	-231,620	-13,180
Cash flows (used in) investing activities	-238,145	-498,742
Cash flows from (used in) financing activities	'	'
Financing costs deferred	-128,181	-305,227
Long term debt issued (Note 6)	2,211,000	6,084,437
Units issued	30,026,500	4,713,787
Long term debt repayment	0	-3,386,630
Debt extinguishment costs	0	-348,420
Share issuance costs	-2,648,813	-433,871
Cash flows from financing activities	29,460,506	6,324,076
Changes in cash and cash equivalents	25,585,193	380,412
Change in cash and cash equivalents due to changes in foreign exchange	327,184	84,954
Cash and cash equivalents, beginning of period	2,813,472	2,283,868
Cash and cash equivalents, end of period	28,725,849	2,749,234

1_Basis_of_Presentation

1. Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
1. Basis of Presentation	'
	These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements for Tribute Pharmaceuticals Canada Inc.’s ("Tribute" or the "Company") most recently completed fiscal year ended December 31, 2013. These unaudited condensed interim financial statements do not include all disclosures required in annual financial statements, but rather are prepared in accordance with recommendations for interim financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). These unaudited condensed interim financial statements have been prepared using the same accounting policies and methods as those used by the Company in the annual audited financial statements for the year ended December 31, 2013, except when disclosed below.
	The unaudited condensed interim financial statements contain all adjustments (consisting of only normal recurring adjustments) which are necessary to present fairly the financial position of the Company as at September 30, 2014, and the results of its operations for the three and nine month periods ended September 30, 2014 and 2013 and its cash flows for the nine month periods ended September 30, 2014 and 2013. Note disclosures have been presented for material updates to the information previously reported in the annual audited financial statements.
		a)	Estimates
	The preparation of these financial statements has required management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of the revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including those related to provision for doubtful accounts, accrued liabilities, income taxes, stock based compensation, revenue recognition, intangible assets and derivative financial instruments. The Company bases its estimates on historical experiences and on various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates. As adjustments become necessary, they are reported in earnings in the period in which they become known.

2_Inventories

2. Inventories	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
2. Inventories	'
		September 30,			December 31,
		2014			2013
	Raw materials	$	256,492	$	236,444
	Finished goods		330,779		418,635
	Packaging materials		54,042		56,007
	Work in process		215,893		333,745
		$	857,206	$	1,044,831

3_Prepaid_Expenses_and_Other_R

3. Prepaid Expenses and Other Receivables	9 Months Ended
	Sep. 30, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
3. Prepaid Expenses and Other Receivables	'
		September 30,			December 31,
		2014			2013
	Prepaid operating expenses	$	225,711	$	140,986
	Deposits		-		18,825
	Interest receivable on loan receivables		6,750		6,075
		$	232,461	$	165,886

4_Property_Plant_and_Equipment

4. Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
4. Property, Plant and Equipment	'
		30-Sep-14
					Accumulated		Net Carrying
			Cost		Amortization		Amount
	Land	$	90,000	$	-	$	90,000
	Building		618,254		293,070		325,184
	Leasehold improvements		10,359		4,144		6,215
	Office equipment		61,308		51,224		10,084
	Manufacturing equipment		1,103,525		598,204		505,321
	Warehouse equipment		17,085		17,085		-
	Packaging equipment		111,270		60,314		50,956
	Computer equipment		136,639		98,391		38,248
		$	2,148,440	$	1,122,432	$	1,026,008
		31-Dec-13
					Accumulated		Net Carrying
			Cost		Amortization		Amount
	Land	$	90,000	$	-	$	90,000
	Building		618,254		269,886		348,368
	Leasehold improvements		10,359		2,590		7,769
	Office equipment		61,308		48,299		13,009
	Manufacturing equipment		1,103,525		576,862		526,663
	Warehouse equipment		17,085		16,737		348
	Packaging equipment		111,270		51,700		59,570
	Computer equipment		130,114		85,922		44,192
		$	2,141,915	$	1,051,996	$	1,089,919

5_Intangible_Assets

5. Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
5. Intangible Assets	'
		30-Sep-14
					Accumulated		Net Carrying
			Cost		Amortization		Amount
	Patents	$	313,743	$	48,188	$	265,555
	Licensing asset		1,005,820		154,742		851,078
	Licensing agreements		10,377,325		2,115,077		8,262,248
		$	11,696,888	$	2,318,007	$	9,378,881
		31-Dec-13
					Accumulated		Net Carrying
			Cost		Amortization		Amount
	Patents	$	268,786	$	39,562	$	229,224
	Licensing asset		1,005,820		96,713		909,107
	Licensing agreements		10,004,000		1,425,158		8,578,842
		$	11,278,606	$	1,561,433	$	9,717,173
	Amortization expense of intangible assets for the three and nine month periods ended September 30, 2014 was $252,203 and $756,574, respectively (2013 - $260,852 and $785,966, respectively).
	The Company has patents pending of $156,909 at September 30, 2014 (December 31, 2013 - $112,902) and licensing agreements of $373,325 (December 31, 2013 - $nil) not currently being amortized.

6_Long_Term_Debt_and_Debt_Issu

6. Long Term Debt and Debt Issuance Costs	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
6. Long Term Debt and Debt Issuance Costs	'
	On August 8, 2013, SWK Funding LLC ("SWK"), a wholly-owned subsidiary of SWK Holdings Corporation, entered into a credit agreement (the "Credit Agreement") with the Company and SWK pursuant thereto, provided to the Company a term loan in the principal amount of US$6,000,000 ($6,381,600) (the "Loan") which was increased, as per the terms of the Credit Agreement, by an additional US$2,000,000 ($2,211,000) at the Company's request on February 4, 2014. SWK served as the agent under the Credit Agreement. The Loan matures on August 8, 2018. Subsequent to September 30, 2014 the Company entered into an amendment to the Credit Agreement (the "Amended Credit Agreement"). See Note 18.
	The Loan accrues interest at an annual rate of 11.5% plus the Libor Rate (as defined in the Credit Agreement), with the Libor Rate being subject to a minimum floor of 2%, such that the minimum interest rate is 13.5%. In the event of a change of control, a merger or a sale of all or substantially all of the Company’s assets, the Loan shall be due and payable.
	Upon receipt of the additional US$2,000,000 ($2,211,000) of the Loan, the Company issued to SWK 347,222 common share purchase warrants with a grant date fair value of the warrants of $120,914. Each warrant entitles SWK to acquire one common share in the capital of the Company at an exercise price of US$0.432 ($0.4612), at any time on or prior to February 4, 2021.
	The discount to the carrying value of the Loan is being amortized as a non-cash interest expense over the term of the Loan using the effective interest rate method. The grant date fair value of the 347,222 warrants issued to SWK was determined using the Black-Scholes model with the following assumptions: expected volatility of 117%, a risk-free interest rate of 1.85%, an expected life of seven years, and no expected dividend yield.
	During the three and nine month periods ended September 30, 2014, the Company accreted $36,738 and $102,264, respectively (2013 - $20,895 and $68,123, respectively) in non-cash accretion expense in connection with the long term loans, which is included in accretion expense on the condensed interim statements of operations, comprehensive income (loss) and deficit.
	During the nine month period ended September 30, 2014, the Company also incurred US$116,169 ($128,425) in legal costs related to the additional US$2,000,000 ($2,211,000) Loan. These fees and costs were classified as debt issuance costs on the balance sheet. These assets are being amortized as a non-cash interest expense over the term of the outstanding Loan using the effective interest rate method. During the three and nine month periods ended September 30, 2014, the Company amortized $29,682 and $82,301, respectively (2013 – $31,263 and $137,092, respectively) in non-cash interest expense, which is included in amortization expense on the condensed interim statements of operations, comprehensive income (loss) and deficit.
	During the nine month period ended September 30, 2014, the Company made no principal payments (year ended December 31, 2013 - US$3,281,250 ($3,386,630)) and interest payments of US$747,000 ($803,393) (year ended December 31, 2013 – US$409,653 ($422,341)) under the previous MidCap Financial LLC loan agreement (now repaid) and SWK loan agreements. The Company has estimated the following revenue-based principal and interest payments over the next five years ended December 31 based on the assumption that only the minimum revenue requirements will be met under the Credit Agreement:
			Principal Payments	Interest Payments
		2014	US$52,035 ($58,321)	US$274,965 ($308,181)
		2015	US$721,460 ($808,612)	US$1,041,040 ($1,166,798)
		2016	US$872,654 ($978,071)	US$934,846 ($1,047,775)
		2017	US$1,001,370 ($1,122,335)	US$806,130 ($903,511)
		2018	US$5,352,481 ($5,999,061)	US$417,053 ($467,433)

7_Capital_Stock

7. Capital Stock	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
7. Capital Stock	'
		(a)	Common Shares
	During the three and nine month periods ended September 30, 2014, the Company completed a public offering in which 42,895,000 units ("Units") were issued at a price of $0.70 per Unit for gross proceeds of $30,026,500. Each Unit consisted of one common share of the Company’s stock and one-half of one common share purchase warrant. Each whole warrant entitles the holder to acquire one common share of the Company at a price per share of $0.90 at any time on or before July 15, 2016. As part of the public offering, the Company issued 21,447,500 common share purchase warrants to the purchasers.
	In connection with the public offering, the Company paid cash commissions to the syndicate of underwriters of $2,251,988 and issued an aggregate of 3,217,125 non-transferable broker units. See Note 7 (c). Each broker unit entitles the holder to purchase one Unit at an exercise price of $0.70 at any time on or before July 15, 2016. Total other issuance costs associated with the public offering were $396,826.
	During the nine month period ended September 30, 2014, the Company issued 500,000 common shares to a consultant for services and recorded $211,812 as paid-in common shares based on the fair market value of the common shares at the date of issuance.
	Common Shares			Number of Shares
							Amount
	Balance, December 31, 2013			51,081,238		$	19,947,290
	Common shares for services issued			500,000			211,812
	Units issued			42,895,000			30,026,500
	Share issuance costs			-			-2,648,813
	Common share purchase warrants – valuation			-			-5,169,881
	Broker warrants - valuation			-			-1,177,468
	Balance, September 30, 2014			94,476,238		$	41,189,440
		(b)	Stock Based Compensation
	The Company’s stock-based compensation program ("Plan") includes stock options in which some options vest based on continuous service, while others vest based on performance conditions such as profitability and sales goals. For those equity awards that vest based on continuous service, compensation expense is recorded over the service period from the date of grant. For performance-based awards, compensation expense is recorded over the remaining service period when the Company determines that achievement is probable.
	During the three and nine month periods ended September 30, 2014, there were 500,000 and 1,827,985 options, respectively, granted to officers, employees and consultants of the Company (2013 – 167,000 and 1,173,250, respectively). The exercise price of 1,107,985 of these options is $0.40, with one-eighth vesting quarterly over two years on each of March 31, June 30, September 30 and December 31, in 2015 and 2016, upon achieving certain financial objectives. Since stock-based compensation is recognized only for those awards that are ultimately expected to vest, the Company has applied an estimated forfeiture rate (based on historical experience and projected employee turnover) to unvested awards for the purpose of calculating compensation expense. The grant date fair value of these options was estimated as $0.33 using the Black-Scholes option pricing model, based on the following assumptions: expected dividend yield of 0%; expected volatility of 123%; expected risk free interest rate of 1.61%; and expected term of 5 years.
	In addition, during the nine month period ended September 30, 2014, 200,000 options were granted with an exercise price of $0.42 and will fully vest on January 3, 2015 (Note 12). The grant date fair value of these options was estimated as $0.39 using the Black-Scholes option pricing model, based on the following assumptions: expected dividend yield of 0%; expected volatility of 123%; expected risk free interest rate of 1.69%; and expected term of 5 years.
	In addition, during the nine month period ended September 30, 2014, 20,000 options were granted with an exercise price of $0.61, with 10,000 vesting on November 30, 2014 and the remaining 10,000 vesting over two years on each of March 31, June 30, September 30 and December 31, in 2015 and 2016. The grant date fair value of these options was estimated as $0.52 using the Black-Scholes option pricing model, based on the following assumptions: expected dividend yield of 0%; expected volatility of 123%; expected risk free interest rate of 1.50%; and expected term of 5 years.
	During the three and nine month periods ended September 30, 2014, 500,000 options were granted to a consultant for services with an exercise price of $0.57. Of these options, 50% will vest on or before February 15, 2015, the remaining 50% will vest one-eighth quarterly over two years, starting in the first quarter following the achievement of certain financial objectives. The grant date fair value of these options was estimated as $0.47 using the Black-Scholes option pricing model, based on the following assumptions: expected dividend yield of 0%; expected volatility of 122%; expected risk free interest rate of 1.56%; and expected term of 5 years.
	For the three and nine month periods ended September 30, 2014, the Company recorded $142,915 and $359,990, respectively (2013 – $138,513 and $428,482, respectively) as additional paid in capital for options issued to directors, officers, employees and consultants based on continuous service. Included in this amount is $48,794 and $85,238, respectively for options issued to consultants for services (Note 12). This expense was recorded as selling, general and administrative expense on the condensed interim statements of operations, comprehensive income (loss) and deficit. Due to termination of employment and non-achievement of performance-based awards, 13,750 options were removed from the number of options issued during the nine month period ended September 30, 2014 (year ended December 31, 2013 – 560,917).
	The activities in additional paid in-capital options are as follows:
			Amount
	Balance, December 31, 2013	$	2,286,890
	Expense recognized for options issued to employees		100,910
	Expense recognized for options issued to consultants		16,222
	Balance, March 31, 2014		2,404,022
	Expense recognized for options issued to employees		79,722
	Expense recognized for options issued to consultants		20,222
	Balance, June 30, 2014		2,503,966
	Expense recognized for options issued to employees		94,121
	Expense recognized for options issued to consultants		48,794
	Balance, September 30, 2014	$	2,646,881
	The total number of options outstanding as at September 30, 2014 was 5,639,070 (December 31, 2013 – 3,824,835). The weighted average grant date fair value of the options granted during the three and nine month periods ended September 30, 2014, was $0.47 and $0.38, respectively (2013 - $0.46 and $0.48, respectively).
	The maximum number of options that may be issued under the Plan is floating at an amount equivalent to 10% of the issued and outstanding common shares, or 9,447,624 as at September 30, 2014 (December 31, 2013 – 5,108,124).
		(c)	Warrants
	As at September 30, 2014, the following warrants were outstanding:
	Warrant Liability
			Number of		Weighted Average					Fair Value at			Fair Value at
	Expiration Date		Warrants		Exercise Price					30-Sep-14			31-Dec-13
	11-May-17		750,000		US$0.43 ($0.48)				$		230,324	$		223,356
	27-Feb-15		4,429,688		US$0.50 ($0.56)				$		451,796	$		518,256
	27-Feb-18		4,429,687		US$0.60 ($0.67)				$		1,375,248	$		1,286,216
	5-Mar-15		1,253,000		US$0.50 ($0.56)				$		130,606	$		146,596
	5-Mar-18		1,253,000		US$0.60 ($0.67)				$		390,413	$		363,825
	11-Mar-15		343,750		US$0.50 ($0.56)				$		36,216	$		49,723
	11-Mar-18		343,750		US$0.60 ($0.67)				$		107,106	$		99,812
	8-Aug-18		755,794		US$0.5954 ($0.6673)				$		327,825	$		245,982
	20-Sep-18		108,696		US$0.55 ($0.62)				$		44,832	$		32,948
	4-Feb-21		347,222		US$0.4320 ($0.4842)				$		156,445	$		-
			14,014,587		US$0.54 ($0.61)				$		3,250,811	$		2,966,714
	In connection with the additional US$2,000,000 ($2,211,000) loan described in Note 6, the Company issued SWK 347,222 common share purchase warrants with each warrant entitling SWK to acquire one common share in the capital of the Company at an exercise price of US$0.432 ($0.4842), at any time on or prior to February 4, 2021. The fair value of the warrant liability at the date of grant was $120,914 and was estimated using the Black-Scholes option pricing model, based on the following assumptions: expected dividend yield of 0%; expected volatility of 117%; risk free interest rate of 1.85%; and expected term of 7 years.
	ASC 815 "Derivatives and Hedging" indicates that warrants with exercise prices denominated in a currency other than an entity’s functional currency should not be classified as equity. As a result, these warrants have been treated as derivatives and recorded as liabilities carried at their fair value, with period-to-period changes in the fair value recorded as a gain or loss in the condensed interim statements of operations, comprehensive income (loss) and deficit. The Company treated the compensation warrants as a liability upon their issuance. The warrant liability is classified as Level 3 within the fair value hierarchy (see Note 16(a)).
	As at September 30, 2014, the fair value of the aggregate warrant liability of $3,250,811 (December 31, 2013 - $2,966,714) was estimated using the Black-Scholes option pricing model based on the following weighted average assumptions: expected dividend yield of 0% (December 31, 2013 – 0%) expected volatility of 97% (December 31, 2013 – 114%) risk-free interest rate of 1.45% (December 31, 2013 – 1.58%) and expected term of 2.29 years (December 31, 2013 – 2.94 years).
	Warrants – Equity
								Grant Date
			Number of		Weighted Average			Fair Value at
	Expiration Date		Warrants		Exercise Price			30-Sep-14
	15-Jul-16		21,447,500		$0.90		$	5,169,881
	15-Jul-16		3,217,125		$0.70		$	1,177,468
			24,664,625		$0.90		$	6,347,349
	In connection with the public offering completed during the nine month period ended September 30, 2014, the Company issued 21,447,500 share purchase warrants to the purchasers, each exercisable into one common share of the Company at $0.90, exercisable at any time on or prior to July 15, 2016. In addition, the Company granted 3,217,125 non-transferable broker units, each exercisable into a Unit of the Company, at an exercise price of $0.70 exercisable at any time on or prior to July 15, 2016. The fair value of the warrants and broker warrants at the date of grant was $6,347,349 and was estimated using the Black-Scholes option pricing model, based on the following assumptions: expected dividend yield of 0%; expected volatility of 99%; risk free interest rate of 1.12%; and expected term of 2 years.

8_Earnings_Loss_Per_Share

8. Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
8. Earnings (Loss) Per Share	'
	The treasury stock method assumes that proceeds received upon the exercise of all warrants and options outstanding in the period is used to repurchase the Company’s shares at the average share price during the period. The diluted earnings (loss) per share is not computed when the effect of such calculation is anti-dilutive. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. Potentially dilutive securities, which were not included in diluted weighted average shares for the nine month period ended September 30, 2014 and the three and nine month periods ended September 30, 2013, consisted of outstanding stock options (4,320,752) and outstanding warrant grants (38,679,212 and 13,667,365, respectively).
	The following table sets forth the computation of earnings (loss) per share:
		For the Three Month Period				For the Nine Month Period
		Ended September 30				Ended September 30
	Numerator:		2014		2013		2014		2013
	Net income (loss) available to common shareholders	$	3,041,875	$	-2,583,576	$	-4,647,145	$	-6,286,035
	Denominator:
	Weighted average number of common shares		87,948,738		50,985,538		64,283,839		48,525,136
	Effect of dilutive common shares		443,589		-		-		-
	Diluted weighted average number of common shares outstanding		88,392,327		50,985,538		64,283,839		48,525,136
	Income (loss) per share – basic and diluted	$	0.03	$	-0.05	$	-0.07	$	-0.13

9_Statement_of_Cash_Flows

9. Statement of Cash Flows	9 Months Ended
	Sep. 30, 2014
Supplemental Cash Flow Elements [Abstract]	'
9. Statement of Cash Flows	'
	Changes in non-cash balances related to operations are as follows:
				For the Nine Months Ended
				30-Sep
			2014						2013
	Accounts receivable	$			-1,331,069	$		-103,781
	Inventories				187,625			-141,943
	Prepaid expenses and other receivables				-66,575		-284,271
	Taxes recoverable				604,310		-283,926
	Accounts payable and accrued liabilities				-130,876		-1,815,265
		$			-736,585	$		-2,629,186
	Included in accounts payable and accrued liabilities at the end of the nine month period ended September 30, 2014, is an amount related to patents and licenses of $8,893 (December 31, 2013 - $14,365) and an amount related to license fees of $186,663 (€125,000) (December 31, 2013 - $nil).
	During the nine month period ended September 30, 2014, there was $803,396 (2013 - $320,029) in interest paid and $nil in taxes paid (2013 – $nil).
	During the nine month period ended September 30, 2014, there was $82,301 (2013 - $137,092) of non-cash debt issuance costs (see Note 6) expensed as amortization of assets.
	During the nine month period ended September 30, 2014, 347,222 warrants were issued and valued at $120,914 in regards to the additional USD$2,000,000 ($2,211,000) advanced under the Credit Agreement (see Note 6).
	During the three and nine month periods ended September 30, 2014, broker warrants were issued and valued at $1,177,468 in regards to the public offering that was completed (Note 7a).

10_Contingencies_and_Commitmen

10. Contingencies and Commitments	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
10. Contingencies and Commitments	'
	The Company has royalty, licensing and manufacturing agreements that have remained in effect for the Company during the quarter. In addition, there were no material changes to the lease agreements during the period.
		(a)	License Agreements
	On December 1, 2011, the Company acquired 100% of the outstanding shares of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. Included in this transaction were the following license agreements:
	On June 30, 2008, Tribute signed a Sales, Marketing and Distribution Agreement with Actavis Group PTC ehf (“Actavis”) to perform certain sales, marketing, distribution, finance and other general management services in Canada in connection with the importation, marketing, sales and distribution of Bezalip® SR and Soriatane® (the “Actavis Products”). On January 1, 2010, a first amendment was signed with Actavis to grant the Company the right and obligation to more actively market and promote the Actavis Products in Canada. On March 31, 2011, a second amendment was signed with Actavis that extended the term of the agreement, modified the terms of the agreement and increased the Company’s responsibilities to include the day-to-day management of regulatory affairs, pharmacovigilance and medical information relating to the Actavis Products. The Company pays Actavis a sales and distribution fee up to an annual base-line net sales forecast plus an incremental fee for incremental net sales above the base-line. On May 4, 2011, the Company signed a Product Development and Profit Share Agreement with Actavis to develop, obtain regulatory approval of and market Bezalip SR in the U.S. The Company shall pay US$5,000,000 ($5,604,000) to Actavis within 30 days of receipt of the regulatory approval to market Bezalip SR in the U.S.
	On November 9, 2010, the Company signed a license agreement with Nautilus Neurosciences, Inc. (“Nautilus”) for the exclusive rights to develop, register, promote, manufacture, use, market, distribute and sell Cambia® in Canada. On August 11, 2011, the Company and Nautilus executed the first amendment to the license agreement and on September 30, 2012 executed the second amendment to the license agreement. Aggregate payments of US$1,000,000 ($1,005,820) were issued under this agreement, which included an upfront payment to Nautilus upon the execution of the agreement and an amount payable upon the first commercial sale of the product. These payments have been included in intangible assets and will be amortized over the life of the license agreement, as amended. Up to US$6,000,000 ($6,724,800) in additional one-time performance based sales milestones, based on a maximum of six different sales tiers, are payable over time, due upon achieving annual net sales ranging from US$2,500,000 ($2,802,000) to US$20,000,000 ($22,416,000) in the first year of the achievement of the applicable milestone. Royalty rates are tiered and payable at rates ranging from 22.5% to 25.0% of net sales.
	On December 30, 2011, the Company signed a license agreement with Apricus Bioscience, Inc. to commercialize MycoVa in Canada. As of September 30, 2014, this product has not been filed with Health Canada and to-date no upfront payments have been paid. Within 10 days of execution of a manufacturing agreement, the Company shall pay an up-front license fee of $200,000. Upon Health Canada approval of MycoVa, the Company shall pay $400,000. Sales milestones payments of $250,000 each are based on the achievement of aggregate net sales in increments of $5,000,000. Royalties are payable at rates ranging from 20% to 25% of net sales.
	On May 13, 2014, the Company entered into an exclusive license and supply agreement with Faes Farma, S.A. (“Faes”), a Spanish pharmaceutical company, for the exclusive right to sell bilastine, a product for the treatment of allergic rhinitis and chronic idiopathic urticaria (hives) in Canada. The exclusive license is inclusive of prescription and non-prescription rights for bilastine, as well as adult and paediatric presentations in Canada. Sales of bilastine are subject to receiving regulatory approval from Health Canada. Payment for the licensing rights is based on an initial fee of €250,000 ($373,325) divided into two equal payments, one on signing €125,000 (($186,663) paid) and the second payment due before December 31, 2014 (€125,000 ($176,913) accrued at September 30, 2014). These payments have been included in intangible assets and will be amortized over the life of the license agreement. Any remaining milestone payments based on the achievement of specific events, including regulatory and sales milestones of up to $3,575,679 (€1,466,600 ($2,075,679) and $1,500,000) are payable over time, beginning with an approval for bilastine from Health Canada. Thereafter, milestones are payable upon attainment of cumulative net sales targets, up to net sales of $60,000,000.
		(b)	Executive Termination Agreements
	The Company currently has employment agreements with the provision of termination and change of control benefits with officers and executives of the Company. The agreements for the officers and executives provide that in the event that any of their employment is terminated during the initial term (i) by the Company for any reason other than just cause or death; (ii) by the Company because of disability; (iii) by the officer or executive for good reason; or (iv) following a change of control, the officers and executives shall be entitled to the balance of the remuneration owing for the remainder of the initial term of up to an aggregate amount of $912,116 as of September 30, 2014 (December 31, 2013 - $792,200) or if a change of control occurs subsequent to the initial term, while the officers or executives are employed on an indefinite basis, a lump sum payment of up to an aggregate amount of $2,079,616 (based on current base salaries).

11_Significant_Customers

11. Significant Customers	9 Months Ended
	Sep. 30, 2014
Risks and Uncertainties [Abstract]	'
11. Significant Customers	'
	During the three month period ended September 30, 2014, the Company had three significant wholesale customers (2013 – two) that represented 68.7% (2013 – 58.7%) of product sales.
	During the nine month period ended September 30, 2014, the Company had three (2013 – two) significant wholesale customers that represented 67.4% (2013 – 57.9%) of product sales.
	The Company believes that its relationship with these customers is satisfactory.

12_Related_Party_Transactions

12. Related Party Transactions	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
12. Related Party Transactions	'
	During the three and nine month periods ended September 30, 2014 the Company granted nil and 200,000 stock options, respectively, to LMT Financial Inc. ("LMT"), a company beneficially owned by a director and former interim officer of the Company, and his spouse for consulting services. For the three and nine month periods ended September 30, 2014, the Company recorded $20,444 and $56,889, respectively as a non-cash expense. During the three and nine month periods ended September 30, 2013 the Company recorded and paid to LMT an aggregate of $6,000 and $42,000, respectively. These amounts have been recorded as selling, general and administrative expense in the condensed interim statements of operations, comprehensive income (loss) and deficit.

13_Income_Taxes

13. Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
13. Income Taxes	'
	The Company has no taxable income under Canadian Federal and Provincial tax laws for the three and nine month periods ended September 30, 2014 and 2013. The Company has non-capital loss carry-forwards at September 30, 2014 totaling approximately $14,903,600, which may be offset against future taxable income. If not utilized, the loss carry-forwards will expire between 2014 and 2034. The cumulative carry-forward pool of SR&ED expenditures as at September 30, 2014, that may be offset against future taxable income, with no expiry date, is $1,798,300.
	The non-refundable portion of the tax credits as at September 30, 2014 was $341,300.

14_Segmented_Information

14. Segmented Information	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
14. Segmented Information	'
	The Company is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada, but has a particular interest in products for the treatment of pain, dermatology and endocrinology/cardiology. The Company also sells Uracyst® and NeoVisc® internationally through a number of strategic partnerships. Currently, all of the Company’s manufacturing assets are located in Canada. All direct sales take place in Canada. Licensing arrangements have been obtained to distribute and sell the Company’s products in various countries around the world.
	Revenue for the three and nine month periods ended September 30, 2014 and 2013 includes products sold in Canada and international sales of products through licensing agreements. Revenue earned is as follows:
				For the Three							For the Nine
				Month Period							Month Period
				Ended September 30							Ended September 30
					2014			2013			2014			2013
		Product sales:
		Domestic sales	$			3,363,814	$		3,022,993	$	10,040,314	$	8,964,777
		International sales				496,152			347,551		1,318,002		1,037,103
		Other revenue				8,950			9,702		27,025		32,554
		Total	$			3,868,916	$		3,380,246	$	11,385,341	$	10,034,434
		Royalty  revenues	$			-	$		99,884	$	18,414	$	197,924
		Total revenues	$			3,868,916	$		3,480,130	$	11,403,755	$	10,232,358
	The Company currently sells its own products and is in-licensing other products in Canada. In addition, revenues include products which the Company out-licenses throughout most countries in Europe, the Caribbean, Austria, Germany, Italy, Lebanon, Kuwait, Malaysia, Portugal, Romania, Spain, South Korea, Turkey, Egypt, Hong Kong and the United Arab Emirates. The operations reflected in the condensed interim statements of operations, comprehensive income (loss) and deficit includes the Company’s activity in these markets.

15_Foreign_Currency_Gain_Loss

15. Foreign Currency Gain (Loss)	9 Months Ended
	Sep. 30, 2014
Foreign Currency [Abstract]	'
15. Foreign Currency Gain (Loss)	'
	The Company enters into foreign currency transactions in the normal course of business. Expenses incurred in currencies other than Canadian dollars are therefore subject to gains or losses due to fluctuations in these currencies. As at September 30, 2014, the Company held cash of $5,117,679 (US$4,079,427 and €385,400) in denominations other than in Canadian dollars (December 31, 2013 - $1,211,602 (US$1,134,686 and €747)); had accounts receivables of $361,354 (US$64,475 and €204,260) denominated in foreign currencies (December 31, 2013 - $258,027 (US$51,395 and €138,964); had accounts payable and accrued liabilities of $41,772 (US$21,755 and €12,286) denominated in foreign currencies (December 31, 2013 – $115,373 (US$72,693 and €25,969)); warrant liability of $3,250,811 (US$2,900,438) (December 31, 2013 - $2,966,714 (US$2,789,315)); and long term debt of $8,966,400 (US$8,000,000) (December 31, 2013 - $6,381,600 (US$6,000,000)). For the three and nine month periods ended September 30, 2014, the Company had a foreign currency loss of $228,065 and $238,572, respectively (2013 – gain of $20,060 and loss of $76,204, respectively). These amounts have been included in selling, general and administrative expenses in the condensed interim statements of operations, comprehensive income (loss) and deficit.

16_Financial_Instruments

16. Financial Instruments	9 Months Ended
	Sep. 30, 2014
Investments, All Other Investments [Abstract]	'
16. Financial Instruments	'
		(a)	Financial assets and liabilities – fair values
	The carrying amounts of cash and cash equivalents, accounts receivable, certain other current assets, accounts payables and accrued liabilities are a reasonable estimate of their fair values because of the short maturity of these instruments.
	Warrant liability and other current asset/liabilities are financial assets/liabilities where fluctuations in market rates will affect the fair value of these financial instruments. The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:
	Level 1: quoted prices in active markets for identical assets or liabilities.
	Level 2: other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly.
	Level 3: techniques which use inputs which have a significant effect on the recorded fair value that are not based on observable market data.
	Cash equivalents and other current asset/liabilities are classified as Level 2 financial instruments within the fair value hierarchy.
		(b)	Derivative liability – warrant liability
	In connection with various financing arrangements, the Company has granted warrants to purchase up to 14,014,587 common shares of the Company as disclosed in Note 7c. The warrants have a weighted average exercise price of US$0.54 ($0.61). The warrants expire at dates ranging from February 27, 2015 to February 4, 2021. The warrants are accounted for as derivative liabilities because the exercise price is denominated in a currency other than the Company’s functional currency.
	The table below summarizes the fair value of the Company’s financial liabilities measured at fair value:
			Fair Value at		Fair Value Measurement Using
			30-Sep-14		Level 1		Level 2		Level 3
	Derivative liability - Warrants	$	3,250,811	$	-	$	-	$	3,250,811
			Fair Value at		Fair Value Measurement Using
			31-Dec-13		Level 1		Level 2		Level 3
	Derivative liability - Warrants	$	2,966,714	$	-	$	-	$	2,966,714
	The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities (warrant derivative liability) for the periods ended September 30, 2014 and December 31, 2013:
		30-Sep-14			31-Dec-13
	Balance at beginning of period	$	2,966,714		$	202,213
	Additions to derivative instruments		120,914			2,365,284
	Change in fair market value, recognized in earnings as Change in    warrant liability		163,183			399,217
	Balance at end of period	$	3,250,811		$	2,966,714
	These instruments were valued using pricing models that incorporate the price of a common share (as quoted on the relevant over-the-counter trading market in the U.S.), volatility, risk free rate, dividend rate and estimated life. The Company computed the value of the warrants using the Black-Scholes model. There were no transfers of assets or liabilities between Level 1, Level 2, or Level 3 during the periods ended September 30, 2014 and December 31, 2013.
	The following are the key weighted average assumptions used in connection with this computation:
			30-Sep-14		31-Dec-13
	Number of shares underlying the warrants		14,014,587		13,667,365
	Fair market value of the stock		US$0.46 ($0.52)		US$0.36($0.38)
	Exercise price		US$0.54 ($0.61)		US$0.55 ($0.58)
	Expected volatility		97%		114%
	Risk-free interest rate		1.45%		1.58%
	Expected dividend yield		0%		0%
	Expected warrant life (years)		2.29		2.94
		(c)	Liquidity risk
	The Company generates sufficient cash from operating and financing activities to fund its operations and fulfill its obligations as they become due. The Company has sufficient funds available through its cash, cash equivalents, and financing arrangements, should its cash requirements exceed cash generated from operations to cover financial liability obligations. The Company’s investment policy is to invest excess cash resources into highly liquid short-term investments purchased with an original maturity of three months or less with tier one financial institutions. As at September 30, 2014, there were no restrictions on the flow of these funds nor have any of these funds been committed in any way, except as outlined in the detailed notes.
	In the normal course of business, management considers various alternatives to ensure that the Company can meet some of its operating cash flow requirements through financing activities, such as private placements of our common stock, preferred stock offerings and offerings of debt and convertible debt instruments as well as through merger or acquisition opportunities. Management may also consider strategic alternatives, including strategic investments and divestitures. As future operations may be financed out of funds generated from financing activities, the Company’s ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the pharmaceutical industry and our securities in particular. Should the Company elect to satisfy its cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that its efforts to obtain such additional funding will be successful, or achieved on terms favorable to the Company or its existing shareholders. If adequate funds are not available on terms favorable to the Company, it may have to reduce substantially or eliminate expenditures such as promotion, marketing or production of its current or proposed products, or obtain funds through other sources such as divestiture or monetization of certain assets or sublicensing (where permitted) of certain rights to certain of its technologies or products.
		(d)	Concentration of credit risk and major customers
	The Company considers its maximum credit risk to be $1,938,649 (December 31, 2013 - $607,580). This amount is the total of the following financial assets: accounts receivable and loan receivable. The Company’s cash and cash equivalents are held through various high grade financial institutions.
	The Company is exposed to credit risk from its customers and continually monitors its customers’ credit. It establishes the provision for doubtful accounts based upon the credit risk applicable to each customer. In line with other pharmaceutical companies, the Company sells its products through a small number of wholesalers and retail pharmacy chains in addition to hospitals, pharmacies, physicians and other groups. Note 11 discloses the significant customer details and the Company believes that the concentrations on the Company’s customers are considered normal for the Company and its industry.
	As at September 30, 2014, the Company had three customers which made up 68.2% of the outstanding accounts receivable in comparison to three customers which made up 38.4% at December 31, 2013. As at September 30, 2014, all outstanding accounts receivable related to product sales were related to three wholesale accounts. As at December 31, 2013 all outstanding accounts receivables were related to product sales, of which $63,722 or 10.8% was related to one wholesale account and $163,220 or 27.6% was related to two international customers.
		(e)	Foreign exchange risk
			The Company principally operates within Canada; however, a portion of the Company’s revenues, expenses, and current assets and liabilities, are denominated in United States dollars and the EURO. The Company’s long term debt is repayable in U.S. dollars, which exposes the Company to foreign exchange risk due to changes in the value of the Canadian dollar. As at September 30, 2014, a 5% change in the foreign exchange rate would increase/decrease the long term debt balance by $400,000 and would increase/decrease both interest expense and net loss by approximately $43,300 for the nine month period ended September 30, 2014. As at September 30, 2014, a 5% change in the foreign exchange rate would increase/decrease the warrant liability balance by $145,000 and would increase/decrease both changes in warrant liability and net loss by $145,000 for the nine month period ended September 30, 2014.
		(f)	Interest rate risk
	The Company is exposed to interest rate fluctuations on its cash and cash equivalents as well as its long term debt. At September 30, 2014, the Company had an outstanding long term debt balance of US$8,000,000 ($8,966,400), which bears interest annually at a rate of 11.5% plus the Libor Rate with the Libor Rate being subject to a minimum floor of 2%, such that that minimum interest rate is 13.5%, which may expose the Company to market risk due to changes in interest rates. For the nine month period ended September 30, 2014, a 1% increase in interest rates would increase interest expense and net loss by approximately $89,700. However, based on current LIBOR interest rates, which are currently under the minimum floor set at 2% and based on historical movements in LIBOR rates, the Company believes a near-term change in interest rates would not have a material adverse effect on the financial position or results of operations.

17_Derivative_Financial_Instru

17. Derivative Financial Instruments	9 Months Ended
	Sep. 30, 2014
Derivative Financial Instruments	'
17. Derivative Financial Instruments	'
	The Company enters into foreign currency contracts with financial institutions to reduce the risk that its cash flows and earnings will be adversely affected by foreign currency exchange rate fluctuations.  In accordance with the Company’s current foreign exchange rate risk management policy, this program is not designated for trading or speculative purposes.
	The Company recognizes derivative instruments as either assets or liabilities in the accompanying balance sheets at fair value.
	During the three and nine month periods ended September 30, 2014, the Company entered into foreign currency call options designated as cash flow hedges to hedge certain forecasted expenses related to its loan obligation denominated in United States Dollars. The notional principal of the foreign currency call option to purchase US$306,000 was $330,052 at October 31, 2014.
	The Company initially reports any gain or loss on the effective portion of the cash flow hedge as a component of other comprehensive income and subsequently reclassifies to the statements of operations when the hedged transaction occurs.
	Valuation techniques used to measure fair value are intended to maximize the use of observable inputs and minimize the use of unobservable inputs.
	The Company has determined the foreign currency call option to be Level 2. The fair value of the foreign currency call option at September 30, 2014 was a gain of $13,158 (December 31, 2013 – a loss of $38,156), and is reported in other current asset/liability in the accompanying balance sheets. During the three month period ended September 30, 2014, the Company recognized a loss on the settled foreign exchange contract of $184,113 (2013 $nil). For the nine month periods ended September 30, 2014, the Company recognized a loss on the settled foreign exchange contract of $180,913 (2013 - $nil).
	At September 30, 2014 and December 31, 2013, the notional principal and fair value of the Company’s outstanding foreign currency derivative financial instruments were as follows:
		30-Sep-14				31-Dec-13
		Notional			Fair Value			Notional Principal			Fair Value
		Principal
	Foreign currency sold – call options	USD$	306,000	$	13,158		USD$		5,000,000	$	-38,156
	The notional principal amounts provide one measure of the transaction volume outstanding as of September 30, 2014 and December 31, 2013, and do not represent the amount of the Company’s exposure to market loss. The estimates of fair value are based on applicable and commonly used pricing models using prevailing financial market information as of September 30, 2014 and December 31, 2013. The amounts ultimately realized upon settlement of these financial instruments, together with the gains and losses on the underlying exposures, will depend on actual market conditions during the remaining life of the instruments.

18_Subsequent_Event

18. Subsequent Event	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
18. Subsequent Event	'
	Amended Credit Agreement
	On October 1, 2014 (the “Amendment Closing Date”), the Company entered into the First Amendment to the Credit Agreement and Guarantee (the “First Amendment”, and, together with the Credit Agreement, the “Amended Credit Agreement”) with SWK. The Amended Credit Agreement provides for a multi-draw term loan to the Company for up to a maximum amount of US$17,000,000 ($19,053,600). On the Amendment Closing Date, SWK advanced the Company an additional amount equal to US$6,000,000 ($6,724,800) pursuant to the terms of a promissory note executed on the Amendment Closing Date (the “October 2014 Note”). The October 2014 Note is for a total principal amount of US$14,000,000 ($15,691,200) (comprised of US$8,000,000 ($8,966,400) advanced under the Credit Agreement and the additional US$6,000,000 ($6,724,800) advanced on October 1, 2014) due and payable on December 31, 2018.  The outstanding principal balance under the October 2014 Note shall bear interest at a rate per annum equal to the LIBOR Rate (subject to a minimum amount of two percent (2.0%)) plus eleven and one-half percent (11.5%), or a minimum interest rate of thirteen and one-half percent (13.5%).
	In addition, on the Amendment Closing Date, the Company issued SWK a warrant (the “Amendment Warrant”) to purchase 740,000 common shares of the Company. The Amendment Warrant is exercisable for a period of five years from the Closing Date at an exercise price of US$0.70, subject to adjustment. SWK may exercise the Amendment Warrant on a cashless basis at any time.
	Asset Purchase Agreement
	On October 2, 2014, the Company entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Novartis AG and Novartis Pharma AG (collectively, “Novartis,” and together with the Company, the “Parties”) pursuant to which the Company acquired from Novartis the Canadian rights to manufacture, market, promote, distribute and sell Fiorinal®, Fiorinal® C, Visken® and Viskazide® for the relief of pain from headache and for the treatment of cardiovascular conditions (the “Products”), as well as certain other assets relating to the Products, including certain intellectual property, marketing authorizations and related data, medical, commercial and technical information, and the partial assignment of certain manufacturing and supply agreements and tenders with third parties (the “Acquired Assets”). The Company also assumed certain liabilities arising out of the Acquired Assets and the Licensed Assets (as described below) after the date hereof, including product liability claims or intellectual property infringement claims by third parties relating to the sale of the Products by the Company in Canada. In connection with the acquisition of the Acquired Assets, and pursuant to the terms of the Asset Purchase Agreement, the Company concurrently entered into a license agreement with Novartis AG, Novartis Pharma AG and Novartis Pharmaceuticals Canada Inc. (the “License Agreement”, and, together with the Asset Purchase Agreement, the “Agreements”). Pursuant to the terms of the License Agreement, the Novartis entities agreed to license to the Company certain assets relating to the Products, including certain intellectual property, marketing authorizations and related data, and medical, commercial and technical information (the “Licensed Assets”). The Company concurrently entered into a supply agreement with Novartis Pharma AG (the “Supply Agreement”), pursuant to which Novartis Pharma AG agreed to supply the Company with the requirements of Products for sale for a transition period until the Company is able to transfer the marketing authorizations to the Company.   The consideration paid for the Acquired Assets and the Licensed Assets was $32,000,000 in cash.

1_Basis_of_Presentation_Policy

1. Basis of Presentation (Policy)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Estimates	'
	Estimates
	The preparation of these financial statements has required management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of the revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including those related to provision for doubtful accounts, accrued liabilities, income taxes, stock based compensation, revenue recognition, intangible assets and derivative financial instruments. The Company bases its estimates on historical experiences and on various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates. As adjustments become necessary, they are reported in earnings in the period in which they become known.

2_Inventories_Tables

2. Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
		September 30,			December 31,
		2014			2013
	Raw materials	$	256,492	$	236,444
	Finished goods		330,779		418,635
	Packaging materials		54,042		56,007
	Work in process		215,893		333,745
		$	857,206	$	1,044,831

3_Prepaid_Expenses_and_Other_R1

3. Prepaid Expenses and Other Receivables (Tables)	9 Months Ended
	Sep. 30, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Schedule of Prepaid Expenses and Other Receivables	'
		September 30,			December 31,
		2014			2013
	Prepaid operating expenses	$	225,711	$	140,986
	Deposits		-		18,825
	Interest receivable on loan receivables		6,750		6,075
		$	232,461	$	165,886

4_Property_Plant_and_Equipment1

4. Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Schedule of Property, Plant and Equipment	'
		30-Sep-14
					Accumulated		Net Carrying
			Cost		Amortization		Amount
	Land	$	90,000	$	-	$	90,000
	Building		618,254		293,070		325,184
	Leasehold improvements		10,359		4,144		6,215
	Office equipment		61,308		51,224		10,084
	Manufacturing equipment		1,103,525		598,204		505,321
	Warehouse equipment		17,085		17,085		-
	Packaging equipment		111,270		60,314		50,956
	Computer equipment		136,639		98,391		38,248
		$	2,148,440	$	1,122,432	$	1,026,008
		31-Dec-13
					Accumulated		Net Carrying
			Cost		Amortization		Amount
	Land	$	90,000	$	-	$	90,000
	Building		618,254		269,886		348,368
	Leasehold improvements		10,359		2,590		7,769
	Office equipment		61,308		48,299		13,009
	Manufacturing equipment		1,103,525		576,862		526,663
	Warehouse equipment		17,085		16,737		348
	Packaging equipment		111,270		51,700		59,570
	Computer equipment		130,114		85,922		44,192
		$	2,141,915	$	1,051,996	$	1,089,919

5_Intangible_Assets_Tables

5. Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Intangible Assets Tables	'
Schedule of Intangible Assets	'
		30-Sep-14
					Accumulated		Net Carrying
			Cost		Amortization		Amount
	Patents	$	313,743	$	48,188	$	265,555
	Licensing asset		1,005,820		154,742		851,078
	Licensing agreements		10,377,325		2,115,077		8,262,248
		$	11,696,888	$	2,318,007	$	9,378,881
		31-Dec-13
					Accumulated		Net Carrying
			Cost		Amortization		Amount
	Patents	$	268,786	$	39,562	$	229,224
	Licensing asset		1,005,820		96,713		909,107
	Licensing agreements		10,004,000		1,425,158		8,578,842
		$	11,278,606	$	1,561,433	$	9,717,173

6_Long_Term_Debt_and_Debt_Issu1

6. Long Term Debt and Debt Issuance Costs (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of payments for Long-term Debt	'
			Principal Payments	Interest Payments
		2014	US$52,035 ($58,321)	US$274,965 ($308,181)
		2015	US$721,460 ($808,612)	US$1,041,040 ($1,166,798)
		2016	US$872,654 ($978,071)	US$934,846 ($1,047,775)
		2017	US$1,001,370 ($1,122,335)	US$806,130 ($903,511)
		2018	US$5,352,481 ($5,999,061)	US$417,053 ($467,433)

7_Capital_Stock_Tables

7. Capital Stock (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Schedule of Common Stock Outstanding	'
	Common Shares			Number of Shares
							Amount
	Balance, December 31, 2013			51,081,238		$	19,947,290
	Common shares for services issued			500,000			211,812
	Units issued			42,895,000			30,026,500
	Share issuance costs			-			-2,648,813
	Common share purchase warrants – valuation			-			-5,169,881
	Broker warrants - valuation			-			-1,177,468
	Balance, September 30, 2014			94,476,238		$	41,189,440
Schedule of Paid-in Capital Options	'
			Amount
	Balance, December 31, 2013	$	2,286,890
	Expense recognized for options issued to employees		100,910
	Expense recognized for options issued to consultants		16,222
	Balance, March 31, 2014		2,404,022
	Expense recognized for options issued to employees		79,722
	Expense recognized for options issued to consultants		20,222
	Balance, June 30, 2014		2,503,966
	Expense recognized for options issued to employees		94,121
	Expense recognized for options issued to consultants		48,794
	Balance, September 30, 2014	$	2,646,881
Schedule of warrants outstanding	'
	Warrant Liability
			Number of		Weighted Average					Fair Value at			Fair Value at
	Expiration Date		Warrants		Exercise Price					30-Sep-14			31-Dec-13
	11-May-17		750,000		US$0.43 ($0.48)				$		230,324	$		223,356
	27-Feb-15		4,429,688		US$0.50 ($0.56)				$		451,796	$		518,256
	27-Feb-18		4,429,687		US$0.60 ($0.67)				$		1,375,248	$		1,286,216
	5-Mar-15		1,253,000		US$0.50 ($0.56)				$		130,606	$		146,596
	5-Mar-18		1,253,000		US$0.60 ($0.67)				$		390,413	$		363,825
	11-Mar-15		343,750		US$0.50 ($0.56)				$		36,216	$		49,723
	11-Mar-18		343,750		US$0.60 ($0.67)				$		107,106	$		99,812
	8-Aug-18		755,794		US$0.5954 ($0.6673)				$		327,825	$		245,982
	20-Sep-18		108,696		US$0.55 ($0.62)				$		44,832	$		32,948
	4-Feb-21		347,222		US$0.4320 ($0.4842)				$		156,445	$		-
			14,014,587		US$0.54 ($0.61)				$		3,250,811	$		2,966,714
Schedule of warrant by expiration date	'
	Warrants – Equity
								Grant Date
			Number of		Weighted Average			Fair Value at
	Expiration Date		Warrants		Exercise Price			30-Sep-14
	15-Jul-16		21,447,500		$0.90		$	5,169,881
	15-Jul-16		3,217,125		$0.70		$	1,177,468
			24,664,625		$0.90		$	6,347,349

8_Loss_Per_Share_Tables

8. Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Computation of Earnings Per Share	'
		For the Three Month Period				For the Nine Month Period
		Ended September 30				Ended September 30
	Numerator:		2014		2013		2014		2013
	Net income (loss) available to common shareholders	$	3,041,875	$	-2,583,576	$	-4,647,145	$	-6,286,035
	Denominator:
	Weighted average number of common shares		87,948,738		50,985,538		64,283,839		48,525,136
	Effect of dilutive common shares		443,589		-		-		-
	Diluted weighted average number of common shares outstanding		88,392,327		50,985,538		64,283,839		48,525,136
	Income (loss) per share – basic and diluted	$	0.03	$	-0.05	$	-0.07	$	-0.13

9_Statement_of_Cash_Flows_Tabl

9. Statement of Cash Flows (Tables)	9 Months Ended
	Sep. 30, 2014
Supplemental Cash Flow Elements [Abstract]	'
Changes in non-cash balances related to operations	'
	Changes in non-cash balances related to operations are as follows:
				For the Nine Months Ended
				30-Sep
			2014						2013
	Accounts receivable	$			-1,331,069	$		-103,781
	Inventories				187,625			-141,943
	Prepaid expenses and other receivables				-66,575		-284,271
	Taxes recoverable				604,310		-283,926
	Accounts payable and accrued liabilities				-130,876		-1,815,265
		$			-736,585	$		-2,629,186

14_Segmented_Information_Table

14. Segmented Information (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting	'
				For the Three							For the Nine
				Month Period							Month Period
				Ended September 30							Ended September 30
					2014			2013			2014			2013
		Product sales:
		Domestic sales	$			3,363,814	$		3,022,993	$	10,040,314	$	8,964,777
		International sales				496,152			347,551		1,318,002		1,037,103
		Other revenue				8,950			9,702		27,025		32,554
		Total	$			3,868,916	$		3,380,246	$	11,385,341	$	10,034,434
		Royalty  revenues	$			-	$		99,884	$	18,414	$	197,924
		Total revenues	$			3,868,916	$		3,480,130	$	11,403,755	$	10,232,358

16_Financial_Instruments_Table

16. Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2014
Derivative Financial Instruments	'
Company's financial liabilities measured at fair value	'
	The table below summarizes the fair value of the Company’s financial liabilities measured at fair value:
			Fair Value at		Fair Value Measurement Using
			30-Sep-14		Level 1		Level 2		Level 3
	Derivative liability - Warrants	$	3,250,811	$	-	$	-	$	3,250,811
			Fair Value at		Fair Value Measurement Using
			31-Dec-13		Level 1		Level 2		Level 3
	Derivative liability - Warrants	$	2,966,714	$	-	$	-	$	2,966,714
Company's Level 3 financial liabilities	'
		30-Sep-14			31-Dec-13
	Balance at beginning of period	$	2,966,714		$	202,213
	Additions to derivative instruments		120,914			2,365,284
	Change in fair market value, recognized in earnings as Change in    warrant liability		163,183			399,217
	Balance at end of period	$	3,250,811		$	2,966,714
Assumptions used in valuation of warrants	'
			30-Sep-14		31-Dec-13
	Number of shares underlying the warrants		14,014,587		13,667,365
	Fair market value of the stock		US$0.46 ($0.52)		US$0.36($0.38)
	Exercise price		US$0.54 ($0.61)		US$0.55 ($0.58)
	Expected volatility		97%		114%
	Risk-free interest rate		1.45%		1.58%
	Expected dividend yield		0%		0%
	Expected warrant life (years)		2.29		2.94

17_Derivative_Financial_Instru1

17. Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2013
Derivative Financial Instruments Tables	'
Notional principal and fair value of the Company's outstanding foreign currency derivative financial instruments	'
		30-Sep-14				31-Dec-13
		Notional Principal			Fair Value			Notional Principal			Fair Value
	Foreign currency sold – call options	USD$	306,000	$	13,158		USD$		5,000,000	$	-38,156

2_Inventories_Details

2. Inventories (Details) (CAD)	Sep. 30, 2014	Dec. 31, 2013
Inventories Details	'	'
Raw materials	256,492	236,444
Finished goods	330,779	418,635
Packaging materials	54,042	56,007
Work in process	215,893	333,745
Inventories	857,206	1,044,831

3_Prepaid_Expenses_and_Other_R2

3. Prepaid Expenses and Other Receivables (Details) (CAD)	Sep. 30, 2014	Dec. 31, 2013
Prepaid Expenses And Other Receivables Details	'	'
Prepaid operating expenses	225,711	140,986
Deposits	0	18,825
Interest receivable on loan receivables	6,750	6,075
Prepaid expenses and other receivables	232,461	165,886

4_Property_Plant_and_Equipment2

4. Property, Plant and Equipment (Details) (CAD)	Sep. 30, 2014	Dec. 31, 2013
Cost	2,148,440	2,141,915
Accumulated Amortization	1,122,432	1,051,996
Net Carrying Amount	1,026,008	1,089,919
Land	'	'
Cost	90,000	90,000
Accumulated Amortization	0	0
Net Carrying Amount	90,000	90,000
Building	'	'
Cost	618,254	618,254
Accumulated Amortization	293,070	269,886
Net Carrying Amount	325,184	348,368
Leasehold Improvements	'	'
Cost	10,359	10,359
Accumulated Amortization	4,144	2,590
Net Carrying Amount	6,215	7,769
Office Equipment	'	'
Cost	61,308	61,308
Accumulated Amortization	51,224	48,299
Net Carrying Amount	10,084	13,009
Manufacturing equipment	'	'
Cost	1,103,525	1,103,525
Accumulated Amortization	598,204	576,862
Net Carrying Amount	505,321	526,663
Warehouse equipment	'	'
Cost	17,085	17,085
Accumulated Amortization	17,085	16,737
Net Carrying Amount	0	348
Packaging equipment	'	'
Cost	111,270	111,270
Accumulated Amortization	60,314	51,700
Net Carrying Amount	50,956	59,570
Computer equipment	'	'
Cost	136,639	130,114
Accumulated Amortization	98,391	85,922
Net Carrying Amount	38,248	44,192

5_Intangible_Assets_Details

5. Intangible Assets (Details) (CAD)	Sep. 30, 2014	Dec. 31, 2013
Cost	11,696,888	11,278,606
Accumulated Amortization	2,318,007	1,561,433
Net Carrying Amount	9,378,881	9,717,173
Patents	'	'
Cost	313,743	268,786
Accumulated Amortization	48,188	39,562
Net Carrying Amount	265,555	229,224
Licensing asset	'	'
Cost	1,005,820	1,005,820
Accumulated Amortization	154,742	96,713
Net Carrying Amount	851,078	909,107
Licensing agreements	'	'
Cost	10,377,325	10,004,000
Accumulated Amortization	2,115,077	1,425,158
Net Carrying Amount	8,262,248	8,578,842

5_Intangible_Assets_Details_Na

5. Intangible Assets (Details Narrative) (CAD)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013
					Patents	Patents	Licensing agreements	Licensing agreements
Amortization expense of intangible assets	252,203	260,852	756,574	785,966	'	'	'	'
Intangible assets pending not amortized	'	'	'	'	156,909	112,902	373,325	0

6_Long_Term_Debt_and_Debt_Issu2

6. Long Term Debt and Debt Issuance Costs (Details) (CAD)	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Principle Payments - 2014	58,321
Principle Payments - 2015	808,612
Principle Payments - 2016	978,071
Principle Payments - 2017	1,122,335
Principle Payments - 2018	5,999,061
Interest Payments - 2014	308,181
Interest Payments - 2015	1,166,798
Interest Payments - 2016	1,047,775
Interest Payments - 2017	903,511
Interest Payments - 2018	467,433

6_Long_Term_Debt_and_Debt_Issu3

6. Long Term Debt and Debt Issuance Costs (Details Narrative) (CAD)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Debt Disclosure [Abstract]	'	'	'	'
Non-cash accretion expense	36,738	20,895	102,264	68,123
Legal Fees	'	'	128,425	'
Non-cash interest expense	29,682	31,263	82,301	137,092

7_Capital_Stock_Details

7. Capital Stock (Details) (CAD)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Begining Balance, Number of Shares	51,081,238
Begining Balance, Amount	19,947,290
Common shares for services issued	500,000
Common shares for services issued, value	211,812
Units issued, Shares	42,895,000
Units issued, Amount	30,026,500
Share issuance costs	-2,648,813
Common share purchase warrants - valuation	-5,169,881
Broker warrants - valuation	-1,177,468
Ending Balance, Number of Shares	94,476,238
Ending Balance, Amount	41,189,440

7_Capital_Stock_Details_1

7. Capital Stock (Details 1) (CAD)	3 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014
Equity [Abstract]	'	'	'
Paid-in Capital Options, Beginning	2,503,966	2,404,022	2,286,890
Expense recognized for options issued to employees	94,121	79,722	100,910
Expense recognized for options issued to consultants	48,794	20,222	16,222
Paid-in Capital Options, Ending	2,646,881	2,503,966	2,404,022

7_Capital_Stock_Details_2

7. Capital Stock (Details 2) (CAD)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Weighted Average Exercise Price	0.61	'
Fair Value	3,250,811	2,966,714
Warrant 1	'	'
Expiration Date	11-May-17	'
Number of Warrants	750,000	'
Weighted Average Exercise Price	0.48	'
Fair Value	230,324	223,356
Warrant 2	'	'
Expiration Date	27-Feb-15	'
Number of Warrants	4,429,688	'
Weighted Average Exercise Price	0.56	'
Fair Value	451,796	518,256
Warrant 3	'	'
Expiration Date	27-Feb-18	'
Number of Warrants	4,429,687	'
Weighted Average Exercise Price	0.67	'
Fair Value	1,375,248	1,286,216
Warrant 4	'	'
Expiration Date	5-Mar-15	'
Number of Warrants	1,253,000	'
Weighted Average Exercise Price	0.56	'
Fair Value	130,606	146,596
Warrant 5	'	'
Expiration Date	5-Mar-18	'
Number of Warrants	1,253,000	'
Weighted Average Exercise Price	0.67	'
Fair Value	390,413	363,825
Warrant 6	'	'
Expiration Date	11-Mar-15	'
Number of Warrants	343,750	'
Weighted Average Exercise Price	0.56	'
Fair Value	36,216	49,723
Warrant 7	'	'
Expiration Date	11-Mar-18	'
Number of Warrants	343,750	'
Weighted Average Exercise Price	0.67	'
Fair Value	107,106	99,812
Warrant 8	'	'
Expiration Date	8-Aug-18	'
Number of Warrants	755,794	'
Weighted Average Exercise Price	0.6673	'
Fair Value	327,825	245,982
Warrant 9	'	'
Expiration Date	20-Sep-18	'
Number of Warrants	108,696	'
Weighted Average Exercise Price	0.62	'
Fair Value	44,832	32,948
Warrant 10	'	'
Expiration Date	4-Feb-21	'
Number of Warrants	347,222	'
Weighted Average Exercise Price	0.4842	'
Fair Value	156,445	'

7_Capital_Stock_Details_Narrat

7. Capital Stock (Details Narrative) (CAD)	3 Months Ended		9 Months Ended			9 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013
						Warrant [Member]	Warrant [Member]
Public offering of common stock, units issued	'	'	'During the three and nine month periods ended September 30, 2014, the Company completed a public offering in which 42,895,000 units ("Units") were issued at a price of $0.70 per Unit for gross proceeds of $30,026,500	'	'	'	'
Common shares issued for services to consultants	'	'	211,812	'	'	'	'
Common shares issued for services to consultants, shares	'	'	500,000	'	'	'	'
Options granted to officers and employees and consultants	500,000	167,000	1,827,985	1,173,250	'	'	'
Expected dividend yield	'	'	'	'	'	0.00%	0.00%
Expected volatility	'	'	'	'	'	123.00%	123.00%
Risk free interest rate	'	'	'	'	'	1.61%	1.49%
Number of options outstanding	5,639,070	'	5,639,070	'	3,824,835	'	'
Weighted average grant date fair value	0.47	0.46	0.38	0.48	'	'	'

8_Loss_Per_Share_Details

8. Loss Per Share (Details) (CAD)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Numerator:	'	'	'	'
Net income (loss) available to common shareholders	3,041,875	-2,583,576	-4,647,145	-6,286,035
Denominator:	'	'	'	'
Weighted average number of common shares	87,948,738	50,985,538	64,283,839	48,525,136
Effect of dilutive common shares	443,589	0	0	0
Diluted weighted average number of common shares outstanding	88,392,327	50,985,538	64,283,839	48,525,136
Income (loss) per share b basic and diluted	0.03	-0.05	-0.07	-0.13

8_Loss_Per_Share_Details_Narra

8. Loss Per Share (Details Narrative)	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Warrant [Member]	'	'	'
Antidilutive securities excluded from earnings	13,667,365	38,679,212	13,667,365
Options	'	'	'
Antidilutive securities excluded from earnings	4,320,752	0	4,320,752

9_Statement_of_Cash_Flows_Deta

9. Statement of Cash Flows (Details) (CAD)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Notes to Financial Statements	'	'
Accounts receivable	-1,331,069	-103,781
Inventories	187,625	-141,943
Prepaid expenses and other receivables	-66,575	-284,271
Taxes recoverable	604,310	-283,926
Accounts payable and accrued liabilities	-130,876	-1,815,265
Changes in non-cash balances related to operations	-736,585	-2,629,186

9_Statement_of_Cash_Flows_Deta1

9. Statement of Cash Flows (Details Narrative) (CAD)	9 Months Ended			12 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013
			Patents and licenses	Patents and licenses	License fees	License fees
Accounts payable and accrued liabilities	-130,876	-1,815,265	8,893	14,365	186,663	0
Interest paid	803,396	320,029	'	'	'	'
Taxes paid	0	0	'	'	'	'
Non-cash debt issuance costs	82,301	137,092	'	'	'	'
Warrants issued, value	1,298,382	0	'	'	'	'

10_Contingencies_and_Commitmen1

10. Contingencies and Commitments (Details Narrative) (CAD)	Sep. 30, 2014	Dec. 31, 2013
Contingencies And Commitments Details Narrative	'	'
Executive termination under initial agreement	912,116	792,200

11_Significant_Customers_Detai

11. Significant Customers (Details Narrative) (Major customer)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Major customer	'	'	'	'
Risk percentage	68.70%	58.70%	67.40%	57.90%
Concentration Risk, Customer	'Three wholesale customers	'Two wholesale customers	'Three wholesale customers	'Two wholesale customers

12_Related_Party_Transactions_

12. Related Party Transactions (Details Narrative) (CAD)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Notes to Financial Statements	'	'	'	'
Non-cash expense	20,444	'	56,889	'
Related Party, consulting services	'	6,000	'	42,000

13_Income_Taxes_Details_Narrat

13. Income Taxes (Details Narrative) (CAD)	9 Months Ended
	Sep. 30, 2014
Non-capital loss carry-forwards	14,903,600
Carry-forward expenditures offset against future taxable income	1,798,300
Tax credits, non-refundable	341,300
Minimum [Member]	'
Loss Carryforwards Expiration Dates	31-Dec-14
Maximum [Member]	'
Loss Carryforwards Expiration Dates	31-Dec-34

14_Segmented_Information_Detai

14. Segmented Information (Details) (CAD)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Jun. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Product sales:	'	'	'	'
Domestic sales	3,363,814	3,022,993	10,040,314	8,964,777
International sales	496,152	347,551	1,318,002	1,037,103
Other revenue	8,950	9,702	27,025	32,554
Total	3,868,916	3,380,246	11,385,341	10,034,434
Royalty revenues	0	99,884	18,414	197,924
Total revenues	3,868,916	3,480,130	11,403,755	10,232,358

15_Foreign_Currency_Gain_Loss_

15. Foreign Currency Gain (Loss) (Details Narrative) (CAD)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Notes to Financial Statements	'	'	'	'
Foreign currency gain /loss	-228,065	20,060	-238,572	-76,204

16_Financial_Instruments_Detai

16. Financial Instruments (Details) (CAD)	Sep. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Derivative liability - Warrants (Fair Value)	3,250,811	2,966,714	2,966,714	202,213
Level 1	'	'	'	'
Derivative liability - Warrants (Fair Value)	0	'	0	'
Level 2	'	'	'	'
Derivative liability - Warrants (Fair Value)	0	'	0	'
Level 3	'	'	'	'
Derivative liability - Warrants (Fair Value)	3,250,811	'	2,966,714	'

16_Financial_Instruments_Detai1

16. Financial Instruments (Details 1) (CAD)	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Financial Instruments Details 1	'	'
Derivative liability - Warrants, beginning	2,966,714	202,213
Additions to derivative instruments	120,914	2,365,284
Change in fair market value, recognized in earnings as Change in warrant liability	163,183	399,217
Derivative liability - Warrants, ending	3,250,811	2,966,714

16_Financial_Instruments_Detai2

16. Financial Instruments (Details 2) (Warrant [Member], CAD)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Warrant [Member]	'	'
Number of shares underlying the warrants	14,014,587	13,667,365
Fair market value of the stock	0.52	0.38
Exercise price	0.61	0.58
Expected volatility	97.00%	114.00%
Risk-free interest rate	1.45%	1.58%
Expected dividend yield	0.00%	0.00%
Expected warrant life (years)	'2 years 3 months 14 days	'2 years 11 months 8 days

16_Financial_Instruments_Detai3

16. Financial Instruments (Details Narrative) (CAD)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Notes to Financial Statements	'	'
Concentration of credit risk and major customers	1,938,649	607,580

17_Derivative_Financial_Instru2

17. Derivative Financial Instruments (Details) (CAD)	Sep. 30, 2014	Dec. 31, 2013
Fair Value	'	'
Foreign currency sold - call options	13,158	-38,156
Notional Principal	'	'
Foreign currency sold - call options	306,000	5,000,000